Apitope   Report issue

For profit Phase 1
Founded: Bristol United Kingdom (2002)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2010
NCT01097668
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Apitope International NV | Apitope Technology (Bristol) Ltd.

Active Ingredients

Drugs in Phase 1 Trials (2)

atx-gd-59 (1 trial)

atx-ms-1467 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graves Disease (Phase 1)

Multiple Sclerosis (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Sclerosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2